The highly successful fourteenth annual BIO-Europe Spring® international partnering conference was a fully digital event in the midst of the worldwide travel restrictions due to the global health emergency. In just 16 days, EBD Group transformed what would have been a Paris conference to an event that welcomed over 1,700 delegates from 986 companies online for nearly 6,000 virtual partnering meetings, with 12 recorded panels featuring industry experts, 45 recorded company presentations, and a virtual exhibit (open to all until April 30) with recorded and downloadable information about the companies.
Two of the panels, concerned the Covid-19 solutions currently being researched and tested, with panelists from Moderna, Johnson & Johnson, CEPI, Regeneron, Omega Funds and Biotechnology Innovation Organization (BIO), as well as the road to recovery in China, with Novartis China, Johnson & Johnson Innovation, the Shanghai Delta Hospital Co., Ark Biosciences, Pharma Intelligence, ChinaBio® Group and the American Chamber Shanghai participating.
Several more panels from the BIO-Europe Spring program will be made available in the coming weeks.
“We are very pleased that we were able to offer BIO-Europe Spring delivered digitally over a five-day span to help the global biotech community keep in touch during this critical time, connecting, dealmaking, and finding investment opportunities,” said Anna Chrisman, Managing Director of EBD Group. “We look forward to returning to Barcelona in 2021 for what we hope will be a long-awaited face-to-face BIO-Europe Spring event.”
BIO-Europe Spring 2021 will be held for the fourth time in Barcelona, Spain, March 22–24, 2021, in collaboration with Biocat and Catalonia Trade & Investment heading up the Host Committee of the BioRegion of Catalonia.
“The fact that Barcelona has been chosen to host BIO-Europe Spring again confirms the international interest in Catalonia as the next place to be,” said Jordi Naval, CEO of Biocat, the organization that champions the healthcare and life sciences ecosystem in Catalonia. “Barcelona ranks in the highest positions of a large number of global rankings in terms of innovation, competitiveness, talent and quality of life, as well as quality of research, number of scientific publications, number of startups and attraction of investment. In fact, the amount of foreign venture capital being invested here has increased ten-fold in five years.”
Naval said, “According to Nature Index, Barcelona is #8 in science output in Europe. Catalonia has unique capacities in genomics and structural biology and stands out in areas like medical chemistry, nanomedicine, omic sciences, bioinformatics and big data. The BioRegion’s capacities in oncology research are particularly noteworthy, covering the whole value chain. Moreover, Catalonia is among the top 10 countries in Europe in terms of participation in clinical trials and among the top 20 in the world; and the top 10 in oncology. But, above all, Catalonia is a land of entrepreneurs: one new company in this sector is created every week.”
The fourteenth annual BIO-Europe Spring® international partnering conference meets for the second time in beautiful Paris, France, March 23–25 at the Paris Expo Porte de Versailles. The event is produced by EBD Group and hosted by Medicen Paris Region, together with Choose Paris Region and the Paris Region Council.
More than 2,500 senior executives from 1,400+ leading international biotech and pharmaceutical companies, investors and business development team members will attend this annual event, held this year in one of Europe’s epicenters for life sciences, bringing together world-renowned research clusters, universities and innovative companies. The region is especially attractive for startups and SMEs thanks to the availability of public and private funding, access to top R&D talent and a massive marketplace.
“We are very excited to work with EBD Group to make their springtime flagship event a big success in Paris,” said Christian Lajoux, Chairman of Medicen Paris Region, the world-class life sciences cluster for the Paris region. “The health-tech ecosystem of the Paris Region is so rich and innovative that it is a great place to find the best experts—clinicians, scientists, startups—to design and build strong collaborative projects and, in the end, high-level therapeutic solutions brought to the market.”
Lajoux said, “Our ecosystem is particularly strong in the fields of digital health, innovative biotherapies, biological diagnostic and medical imaging, applied to all therapeutic areas (oncology, neurosciences, immunology, infectiology, rare diseases).”
“BIO-Europe Spring is the most significant industry event of the new year where top executives from global biotech, pharma and finance come together with hundreds of potential partners to negotiate favorable deals for developing therapies and cures,” said Pam Putz, Managing Director Europe for EBD Group. “We’re so happy to bring this event back to the wonderful city of Paris.”
EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.
Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio® Partnering Forum, Rare Disease Innovation and Partnering Summit, Connecting Cancer, Imagine Health Summit, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.
Biotech Showcase, the investor conference driving therapeutic innovation, advances in digital medicine, and broad industry collaboration, had more than 3,800 attendees, marking rising participation every year since the first meeting 12 years ago. This year’s Biotech Showcase took place in the third week of January and was produced by Demy-Colton and EBD Group.
“We’re thrilled to share that we’ve had another record year of investor attendance, company presentations, and partnering meetings at Biotech Showcase,” said Sara Jane Demy, founder and CEO, Demy-Colton. “For many in the biotech and healthcare space, this is one of the most important business weeks during their calendar year, where companies can have multiple meetings with serious investors and potential collaborators all in one place. We are proud to produce an event that is welcoming, unique and provides a highly valuable opportunity for today’s innovative biotechnology companies to connect and share their therapeutic advances with the larger community.”
“This year, Biotech Showcase attracted over 400 presenting companies and more than 1,000 investors resulting in a remarkable level of engagement. Our plenary sessions and workshops were extremely popular and focused on some of the industry’s biggest challenges,” said Tina Gunnink, Managing Director, EBD Group US. “As we move into the new decade, it will be exciting to see how the investments and partnerships initiated at Biotech Showcase evolve and affect the healthcare landscape.”
Biotech Showcase’s robust program featured panels highlighting advancements in women’s health and rare disease, as well as discussions on drug pricing and the potential impact of the upcoming election. This year’s concurrent events, Digital Medicine & Medtech Showcase and China Showcase, also saw record attendees and included panels on the impact of artificial intelligence and the international investment and partnering landscape.
The images and text displayed above are under the copyright law and authority of the holder of the event and image and will not be used for any marketing, financial and profiteering of any kind. The Goal of these articles is merely further publicity.